Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving tadasitamab and rituximab may work well to treat patients with newly diagnosed follicular lymphoma.

NCT Number	NCT07731789
Lead Sponsor	University of Washington Collaborators: Incyte Corporation
Conditions	Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Enrollment	30 participants
Start Date	2026-10-31
Primary Completion	2030-10-31 (estimated)
Study Completion	2032-10-29 (estimated)
Updated on ClinicalTrials.gov	2026-07-28